571 A focused, PCR based gene expression signature to refine grade in breast cancer

Molecular genetic tests in the prediction of the prognosis of breast cancer

“…Data suggest a benefi t for determining metastasis-free survival in ER+ breast cancers independent of lymph node status or tumour size [19]. Th is data set was also shown to predict metastasis-free Tab 3-gene (CYP24, PDCD6IP, and BIRC5) FFPE [25] Expression array/RNA 70-gene Amsterdam Frozen [26] 76-gene Rotterdam Frozen [15] 97-gene Genomic Grade Index Frozen [13] 163-gene Stroma-derived Prognostic Predictor Frozen [21] 459-gene Wound-response signature Frozen [19] qPCR/RNA 21-gene (Recurrence Score) FFPE [11] 4-gene (MYBL2, KPNA2, CDC2, CDC20) FFPE [27] 5-gene (HOXB13, IL17BR, CHDH, MIB1, MKI67) FFPE [28] 8-gene (TOPFOX) FFPE [22] 14-gene (Metastasis Test) FFPE [16] 50-gene (PAM50) FFPE [9] IHC/protein ER FFPE PgR FFPE HER2 FFPE [7] Ki67 FFPE [29] IHC4 (ER, PgR, HER2, Ki67) FFPE 5-marker (p53, NDRG1, CEACAM5, SLC7A5, and HTF9C) FFPE [30] survival in medulloblastoma, as well as lung and prostate cancers [20].…”

“…Recently, a chromosomal instability expression signature refl ecting tumour aneuploidy was identifi ed by our group, and was able to stratify outcome in grade 2 primary breast cancer [22]. FFPE tissue blocks -routine pathology material -are suitable for this test.…”